HeartBeam Study Shows Comparable Accuracy Between Portable 3D ECG System and Standard 12-Lead ECG
HeartBeam Inc. reported study results demonstrating that its portable 3D ECG system achieves comparable accuracy to standard 12-lead ECGs in detecting cardiac arrhythmias, potentially expanding advanced cardiac monitoring to non-clinical settings.
HeartBeam Inc. (NASDAQ: BEAT) announced study results showing no significant differences in detecting atrial fibrillation, atrial flutter, and sinus rhythm when its deep learning algorithms were applied to the HeartBeam System versus standard 12-lead ECGs. Data from 201 patients, presented at HRX Live 2025 in Atlanta by Dr. Joshua Lampert of Mount Sinai Heart, demonstrated high accuracy rates in both groups (94.5% HeartBeam vs. 95.5% standard 12-lead).
CEO Rob Eno stated that these findings highlight the potential of HeartBeam's compact, 3D device to expand advanced cardiac monitoring to settings where full 12-lead ECGs may be impractical. The company plans to use these results to support future FDA submissions for its innovative cardiac monitoring technology.
The significance of this development lies in its potential to transform cardiac care delivery. Traditional 12-lead ECGs require specialized equipment and clinical settings, limiting their accessibility. HeartBeam's cable-free device, capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG, could enable remote monitoring and early detection of cardiac conditions outside medical facilities.
HeartBeam's technology represents a major advancement in portable cardiac diagnostics. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, while its 12-lead ECG synthesis software remains under FDA review. With over 20 issued patents related to technology enablement, HeartBeam is positioned to redefine cardiac health management through accessible, actionable heart intelligence.
The study results validate the clinical utility of HeartBeam's approach and support the company's mission to make advanced cardiac monitoring more widely available. This could lead to earlier detection of arrhythmias and improved patient outcomes through timely intervention, particularly for patients in remote or underserved areas where traditional ECG equipment may not be readily available.